{"id":493282,"date":"2024-06-04T17:54:47","date_gmt":"2024-06-04T17:54:47","guid":{"rendered":"https:\/\/www.olympiajournal.com\/news\/story\/493282\/er-her2-ve-breast-cancer-pipeline-analysis-2024-clinical-trials-fda-ema-pmda-approvals-emerging-therapies-and-growth-prospects.html"},"modified":"2024-06-04T17:54:47","modified_gmt":"2024-06-04T17:54:47","slug":"er-her2-ve-breast-cancer-pipeline-analysis-2024-clinical-trials-fda-ema-pmda-approvals-emerging-therapies-and-growth-prospects","status":"publish","type":"post","link":"https:\/\/www.oklahomanews-online.com\/news\/story\/493282\/er-her2-ve-breast-cancer-pipeline-analysis-2024-clinical-trials-fda-ema-pmda-approvals-emerging-therapies-and-growth-prospects.html","title":{"rendered":"ER+\/ HER2 -ve Breast Cancer Pipeline Analysis 2024: Clinical Trials, FDA, EMA, PMDA Approvals, Emerging Therapies, and Growth Prospects"},"content":{"rendered":"<div style=\"float:right;width:250px;padding:8px 10px 10px 10px\"><a rel=\"nofollow noopener\" href=\"https:\/\/www.abnewswire.com\/uploads\/1717517768.jpeg\" style=\"border:none !important\" target=\"_blank\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"ER+\/ HER2 -ve Breast Cancer Pipeline Analysis 2024: Clinical Trials, FDA, EMA, PMDA Approvals, Emerging Therapies, and Growth Prospects\" src=\"https:\/\/www.abnewswire.com\/uploads\/1717517768.jpeg\" alt=\"ER+\/ HER2 -ve Breast Cancer Pipeline Analysis 2024: Clinical Trials, FDA, EMA, PMDA Approvals, Emerging Therapies, and Growth Prospects\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify\">DelveInsight&rsquo;s,<strong>&nbsp;&ldquo;ER+\/ HER2-VE Breast Cancer Pipeline Insight 2024&rdquo;<\/strong>&nbsp;report provides comprehensive insights about&nbsp;<strong>40+ companies and 50+ pipeline drugs<\/strong>&nbsp;in ER+\/ HER2-VE Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Key Takeaways from the ER+\/ HER2 -ve Breast Cancer Pipeline Outlook Report<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>DelveInsight&rsquo;s ER+\/ HER2 -ve Breast Cancer pipeline report depicts a robust space with 40+ active players working to develop 50+ pipeline therapies for ER+\/ HER2 -ve Breast Cancer treatment.<\/li>\n<li>The leading ER+\/ HER2 -ve Breast Cancer Companies such as BeiGene, H3 Biomedicine, AstraZeneca, Olema Pharmaceuticals, CytomX Therapeutics, Roche, G1 Therapeutics, Sanofi, Jiangsu HengRui Medicine, and others.<\/li>\n<li>Promising ER+\/ HER2 -ve Breast Cancer Therapies such as G1T48, Palbociclib, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Request a sample and discover the recent advances in ER+\/ HER2 -ve Breast Cancer @ <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/sample-request\/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">ER+\/ HER2 -ve Breast Cancer Pipeline Outlook Report<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>ER+\/ HER2 -ve Breast Cancer Overview<\/strong><\/p>\n<p style=\"text-align: justify\">HR+ breast cancers are those that express estrogen receptors (ER) or progesterone receptors (PR) or both. These tumors account for 70&ndash;80% of all breast cancers. These hormone-dependent cancers can often be treated successfully with a variety of drugs that modulate ER or reduce estrogen. HER2 is short for human epidermal growth factor receptor. HER2 is sometimes called ERBB2, which stands for Erb-B2 receptor tyrosine kinase. HER2 is a gene that produces HER2 proteins, or receptors. If breast cancer cells don&rsquo;t have abnormal levels of HER2 proteins, the breast cancer is considered HER2-negative.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>ER+\/ HER2 -ve Breast Cancer Emerging Drugs Profile<\/strong><\/p>\n<p style=\"text-align: justify\"><strong>&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li><strong>AZD9833: Astrazeneca<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify\">AZD-9833 acts as selective estrogen receptor degraders. It is being developed as combination therapy with palbociclib (a CDK4\/6 inhibitor). It is currently in Phase III stage of dvelopement and is being developed by Astrazeneca.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<ul style=\"text-align: justify\">\n<li><strong>BGB-290: BeiGene<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify\">Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated for the treatment of HER2 Negative Breast Cancer. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1\/2 mutated ovarian cancers. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene&rsquo;s investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumor malignancies. It is currently in Phase II stage of development for HER2-Negative Breast Cancer and is being developed by Beigene.<\/p>\n<p style=\"text-align: justify\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Learn more about ER+\/ HER2 -ve Breast Cancer in clinical trials @ <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/sample-request\/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">ER+\/ HER2 -ve Breast Cancer Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify\"><strong>ER+\/ HER2 -ve Breast Cancer Therapeutics Assessment<\/strong><\/p>\n<p style=\"text-align: justify\">There are approx.&nbsp;40+ key companies&nbsp;which are developing the ER+\/ HER2-VE Breast Cancer. The ER+\/ HER2 -ve Breast Cancer companies which have their ER+\/ HER2-VE Breast Cancer drug candidates in the most advanced stage, i.e. Phase III include,&nbsp;<strong>Astrazeneca<\/strong>.<\/p>\n<p style=\"text-align: justify\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify\"><strong>DelveInsight&rsquo;s ER+\/ HER2 -ve Breast Cancer pipeline report covers around&nbsp;50+ products&nbsp;under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>Late-stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage products (Phase I\/II and Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<li>Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Discover more about ER+\/ HER2 -ve Breast Cancer in development @ <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/sample-request\/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">ER+\/ HER2 -ve Breast Cancer Clinical Trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>ER+\/ HER2 -ve Breast Cancer Companies<\/strong><\/p>\n<p style=\"text-align: justify\">BeiGene, H3 Biomedicine, AstraZeneca, Olema Pharmaceuticals, CytomX Therapeutics, Roche, G1 Therapeutics, Sanofi, Jiangsu HengRui Medicine, and others.<\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>ER+\/ HER2-VE Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>Infusion<\/li>\n<li>Intradermal<\/li>\n<li>Intramuscular<\/li>\n<li>Intranasal<\/li>\n<li>Intravaginal<\/li>\n<li>Oral<\/li>\n<li>Parenteral<\/li>\n<li>Subcutaneous<\/li>\n<li>Topical<\/li>\n<li>Molecule Type<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify\"><strong>ER+\/ HER2 -ve Breast Cancer Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>Vaccines<\/li>\n<li>Monoclonal Antibody<\/li>\n<li>Peptides<\/li>\n<li>Polymer<\/li>\n<li>Small molecule<\/li>\n<li>Product Type<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>To know more about ER+\/ HER2 -ve Breast Cancer, visit @ <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/sample-request\/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">ER+\/ HER2 -ve Breast Cancer Segmentation<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Scope of the ER+\/ HER2 -ve Breast Cancer Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>Coverage- Global<\/li>\n<li>ER+\/ HER2 -ve Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>ER+\/ HER2 -ve Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<li>ER+\/ HER2 -ve Breast Cancer Companies- BeiGene, H3 Biomedicine, AstraZeneca, Olema Pharmaceuticals, CytomX Therapeutics, Roche, G1 Therapeutics, Sanofi, Jiangsu HengRui Medicine, and others.<\/li>\n<li>ER+\/ HER2 -ve Breast Cancer Therapies- G1T48, Palbociclib, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>For further information on the ER+\/ HER2 -ve Breast Cancer Pipeline Therapeutics, reach out @ <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/sample-request\/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">ER+\/ HER2 -ve Breast Cancer Products Development<\/a><\/strong><\/p>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>ER+\/ HER2-VE Breast Cancer: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>AZD9833: Astrazeneca<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>BGB-290: BeiGene<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Early Stage Products (Phase I\/II)<\/li>\n<li>OP-1250: Olema Pharmaceuticals<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Preclinical Stage Products<\/li>\n<li>Drug Name: Company Name<\/li>\n<li>Drug profiles in the detailed report&hellip;..<\/li>\n<li>Inactive Products<\/li>\n<li>ER+\/ HER2-VE Breast Cancer Key Companies<\/li>\n<li>ER+\/ HER2-VE Breast Cancer Key Products<\/li>\n<li>ER+\/ HER2-VE Breast Cancer- Unmet Needs<\/li>\n<li>ER+\/ HER2-VE Breast Cancer- Market Drivers and Barriers<\/li>\n<li>ER+\/ HER2-VE Breast Cancer- Future Perspectives and Conclusion<\/li>\n<li>ER+\/ HER2-VE Breast Cancer Analyst Views<\/li>\n<li>ER+\/ HER2-VE Breast Cancer Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify\">&nbsp;<\/p>\n<p style=\"text-align: justify\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p class=\"caps\"><span style='font-size:18px !important'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=er-her2-ve-breast-cancer-pipeline-analysis-2024-clinical-trials-fda-ema-pmda-approvals-emerging-therapies-and-growth-prospects\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9650213330<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=er-her2-ve-breast-cancer-pipeline-analysis-2024-clinical-trials-fda-ema-pmda-approvals-emerging-therapies-and-growth-prospects\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s,&nbsp;&ldquo;ER+\/ HER2-VE Breast Cancer Pipeline Insight 2024&rdquo;&nbsp;report provides comprehensive insights about&nbsp;40+ companies and 50+ pipeline drugs&nbsp;in ER+\/ HER2-VE Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/posts\/493282"}],"collection":[{"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/comments?post=493282"}],"version-history":[{"count":0,"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/posts\/493282\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/media?parent=493282"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/categories?post=493282"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/tags?post=493282"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}